FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2613379575> ?p ?o ?g. }

• W2613379575 endingPage "248" @default.
• W2613379575 startingPage "243" @default.
• W2613379575 abstract "Patients with moderate-to-severe atopic dermatitis (AD) report a multidimensional disease burden that includes impaired health-related quality-of-life (HRQoL). Changes in overall health status and specific dimensions that contribute to HRQoL were evaluated in adults with moderate-to-severe AD who participated in phase 3 clinical trials of dupilumab, which is a fully human monoclonal antibody that inhibits signaling of cytokines IL-4 and IL-13.Two dupilumab phase 3 clinical trials of identical design included the 5-dimension 3-level EuroQol (EQ-5D) as a measure of HRQoL. EQ-5D data from the two trials were pooled in an analysis that, using analysis of covariance, compared subcutaneous dupilumab 300 mg once weekly (qw) or every 2 weeks (q2w) versus placebo for EQ-5D utility score change from baseline overall and for clinical responders. The proportions of patients who reported different levels of problems on the individual dimension of the EQ-5D were also compared by treatment group.Patients (n = 1379) were 57.9% male with a mean (SD) age of 38.3 (14.3) years; baseline EQ-5D utility scores ranged from 0.611 to 0.629 across treatment groups. EQ-5D least squares mean change from baseline at week 16 was 0.031 with placebo, and was significantly greater with dupilumab qw (0.207) and q2w (0.210) (both P < 0.0001), which exceeded the minimal clinically important difference and resulted in scores that approached population norms. Changes from baseline among patients who achieved AD clinical response were greater than changes among the total population. Improvements were driven by the individual EQ-5D dimensions with the greatest burden at baseline (i.e., pain/discomfort, anxiety/depression and usual activities).In adults with moderate-to-severe AD, dupilumab resulted in improvements in HRQoL that were statistically significant relative to placebo and were clinically meaningful.Sanofi and Regeneron Pharmaceuticals, Inc.ClinicalTrials.gov identifiers, NCT02277743 and NCT02277769, EudraCT Numbers 2014-001198-15 and 2014-002619-40." @default.
• W2613379575 created "2017-05-19" @default.
• W2613379575 creator A5015905197 @default.
• W2613379575 date "2017-05-13" @default.
• W2613379575 modified "2023-10-17" @default.
• W2613379575 title "Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials" @default.
• W2613379575 cites W102833839 @default.
• W2613379575 cites W2076272659 @default.
• W2613379575 cites W2100770509 @default.
• W2613379575 cites W2117359358 @default.
• W2613379575 cites W2200308911 @default.
• W2613379575 cites W2276335262 @default.
• W2613379575 cites W2524051065 @default.
• W2613379575 doi "https://doi.org/10.1007/s13555-017-0181-6" @default.
• W2613379575 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5453923" @default.
• W2613379575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28503712" @default.
• W2613379575 hasPublicationYear "2017" @default.
• W2613379575 type Work @default.
• W2613379575 sameAs 2613379575 @default.
• W2613379575 citedByCount "32" @default.
• W2613379575 countsByYear W26133795752017 @default.
• W2613379575 countsByYear W26133795752018 @default.
• W2613379575 countsByYear W26133795752019 @default.
• W2613379575 countsByYear W26133795752020 @default.
• W2613379575 countsByYear W26133795752021 @default.
• W2613379575 countsByYear W26133795752022 @default.
• W2613379575 countsByYear W26133795752023 @default.
• W2613379575 crossrefType "journal-article" @default.
• W2613379575 hasAuthorship W2613379575A5015905197 @default.
• W2613379575 hasBestOaLocation W26133795751 @default.
• W2613379575 hasConcept C126322002 @default.
• W2613379575 hasConcept C142724271 @default.
• W2613379575 hasConcept C159110408 @default.
• W2613379575 hasConcept C16005928 @default.
• W2613379575 hasConcept C168563851 @default.
• W2613379575 hasConcept C1862650 @default.
• W2613379575 hasConcept C204787440 @default.
• W2613379575 hasConcept C27081682 @default.
• W2613379575 hasConcept C2778329239 @default.
• W2613379575 hasConcept C2779824493 @default.
• W2613379575 hasConcept C2779951463 @default.
• W2613379575 hasConcept C2780699399 @default.
• W2613379575 hasConcept C2908647359 @default.
• W2613379575 hasConcept C535046627 @default.
• W2613379575 hasConcept C71924100 @default.
• W2613379575 hasConcept C99454951 @default.
• W2613379575 hasConceptScore W2613379575C126322002 @default.
• W2613379575 hasConceptScore W2613379575C142724271 @default.
• W2613379575 hasConceptScore W2613379575C159110408 @default.
• W2613379575 hasConceptScore W2613379575C16005928 @default.
• W2613379575 hasConceptScore W2613379575C168563851 @default.
• W2613379575 hasConceptScore W2613379575C1862650 @default.
• W2613379575 hasConceptScore W2613379575C204787440 @default.
• W2613379575 hasConceptScore W2613379575C27081682 @default.
• W2613379575 hasConceptScore W2613379575C2778329239 @default.
• W2613379575 hasConceptScore W2613379575C2779824493 @default.
• W2613379575 hasConceptScore W2613379575C2779951463 @default.
• W2613379575 hasConceptScore W2613379575C2780699399 @default.
• W2613379575 hasConceptScore W2613379575C2908647359 @default.
• W2613379575 hasConceptScore W2613379575C535046627 @default.
• W2613379575 hasConceptScore W2613379575C71924100 @default.
• W2613379575 hasConceptScore W2613379575C99454951 @default.
• W2613379575 hasFunder F4320307781 @default.
• W2613379575 hasFunder F4320311600 @default.
• W2613379575 hasIssue "2" @default.
• W2613379575 hasLocation W26133795751 @default.
• W2613379575 hasLocation W26133795752 @default.
• W2613379575 hasLocation W26133795753 @default.
• W2613379575 hasLocation W26133795754 @default.
• W2613379575 hasOpenAccess W2613379575 @default.
• W2613379575 hasPrimaryLocation W26133795751 @default.
• W2613379575 hasRelatedWork W2524051065 @default.
• W2613379575 hasRelatedWork W2783035220 @default.
• W2613379575 hasRelatedWork W2921337698 @default.
• W2613379575 hasRelatedWork W2995377367 @default.
• W2613379575 hasRelatedWork W3010474792 @default.
• W2613379575 hasRelatedWork W3189569397 @default.
• W2613379575 hasRelatedWork W3204561650 @default.
• W2613379575 hasRelatedWork W3210501554 @default.
• W2613379575 hasRelatedWork W3211634059 @default.
• W2613379575 hasRelatedWork W4295338524 @default.
• W2613379575 hasVolume "7" @default.
• W2613379575 isParatext "false" @default.
• W2613379575 isRetracted "false" @default.
• W2613379575 magId "2613379575" @default.
• W2613379575 workType "article" @default.